Nebenwirkungen · NeoRecormon
NeoRecormon 500 IU solution for injection in pre-filled syringe NeoRecormon 2 000 IU solution for injection in pre-filled syringe NeoRecormon 3 000 IU solution for injection in pre-filled syringe NeoRecormon 4 000 IU solution for injection in pre-filled syringe NeoRecormon 5 000 IU solution for injection in pre-filled syringe NeoRecormon 6 000 IU solution for injection in pre-filled syringe NeoRecormon 10 000 IU solution for injection in pre-filled syringe NeoRecormon 20 000 IU solution for injection in pre-filled syringe NeoRecormon 30 000 IU solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 11
HOS-086027 · Präparat HOS-083248
Shunt thromboses may occur, especially in patients who have a tendency to hypotension or whose arteriovenous fistulae exhibit complications (e.g. stenoses, aneurisms), see section 4.4. In most cases, a fall in serum ferritin values simultaneous with a rise in packed cell volume is observed (see section 4.4). In addition, transient increases in serum potassium and phosphate levels have been observed in isolated cases (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-02T10:00:00Z · SHA-256 d4885cc4a4f4b8eee4e66452aecdcfd9e0cb2d83ca77d038cff33e2a87f9cdac · Passage 5cfa3e6a9aebf6772062cf9f942b449e8a947c435d9c39602e98cf79fc949039 · Zeichen 734–1172 im Abschnitt